The activity of cytochrome P450 CYP2B in rat liver during neuroleptic treatment.
The aim of the present study was to investigate the influence of classic and atypical neuroleptics on the activity of rat CYP2B measured as a rate of 16 beta-hydroxylation of testosterone. The reaction was studied in control liver microsomes in the presence of neuroleptics, as well as in microsomes of rats treated intraperitoneally for one day or two weeks (twice a day) with pharmacological doses (mg/kg) of the drugs (promazine, levomepromazine, thioridazine and perazine, 10 each; chlorpromazine 3; haloperidol 0.3; risperidone 0.1; sertindole 0.05), in the absence of the neuroleptics in vitro. ome of the neuroleptics added in vitro to control liver microsomes decreased the activity of CYP2B. The obtained Ki values indicated that thioridazine was the most potent inhibitor of the studied reaction (Ki = 26 microM). The inhibitory effects of chlorpromazine, perazine and sertindole were moderate (Ki = 45-75 microM), while promazine, haloperidol, levomepromazine, and risperidone were rather weak inhibitors of CYP2B activity (Ki = 125-225 microM, respectively). After a one-day (i.e. 24 h) exposure of rats to the investigated neuroleptics, the decreased CYP2B activity was observed after haloperidol, risperidone and sertindole. All the investigated neuroleptics did not produce any significant effect on CYP2B activity when administered in vivo for two weeks. Considering relatively high pharmacological/therapeutic doses and liver concentrations of phenothiazines, it seems that the direct inhibitory effect of those neuroleptics with Ki values below 100 microM found in vitro (thioridazine, chlorpromazine, perazine), as well as indirect effects produced by one-day treatment with haloperidol, risperidone or sertindole may be of some physiological, pharmacological or toxicological importance in vivo.
Department of Pharmacokinetics and Drug Metabolism, Institute of Pharmacology, Polish Academy of Sciences, Smetna 12, PL 31-343 Kraków, Poland.
Anna
A
Haduch
Jacek
J
Wójcikowski
Władysława A
WA
Daniel
D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology*; D001189:Aryl Hydrocarbon Hydroxylases / Q000378:metabolism*; D019362:Cytochrome P-450 CYP2B1 / Q000378:metabolism*; D066298:In Vitro Techniques; D007527:Isoenzymes / Q000378:metabolism; D008099:Liver / Q000187:drug effects* / Q000201:enzymology; D008297:Male; D008862:Microsomes, Liver / Q000187:drug effects / Q000201:enzymology; D051381:Rats; D017208:Rats, Wistar; D013250:Steroid Hydroxylases / Q000378:metabolism*; D013739:Testosterone / Q000378:metabolism
D014150:Antipsychotic Agents; D007527:Isoenzymes; D013739:Testosterone; D013250:Steroid Hydroxylases; D001189:Aryl Hydrocarbon Hydroxylases; D019362:Cytochrome P-450 CYP2B1; C025619:steroid 16-beta-hydroxylase